Discovery and optimization of withangulatin A derivatives as novel glutaminase 1 inhibitors for the treatment of triple-negative breast cancer

To develop novel GLS1 inhibitors as effective therapeutic agents for triple-negative breast cancer (TNBC), 25 derivatives were synthesized from the natural inhibitor withangulatin A (IC50 = 18.2 mM). Bioassay optimization identified a novel and selective GLS1 inhibitor 7 (IC50 = 1.08 mu M). In MDA-MB-231 cells, 7 diminished cellular glutamate levels by blocking glutaminolysis pathway, further triggering the generation of reactive oxygen species to induce caspase-dependent apoptosis. Molecular docking indicated that 7 interacted with a new reacting site of allosteric binding pocket by forming various interactions in GLS1. The intraperitoneal administration of 7 at a dose of 50 mg/kg exhibited remarkable therapeutic effects and no apparent toxicity in the MDA-MB-231 xenograft model, indicating its potential as a novel GLS1 inhibitor for treatment of TNBC. (C) 2020 Elsevier Masson SAS. All rights reserved.

Automated summary

A potential novel GLS1 inhibitor has been developed through synthesis and optimization, showing effective therapeutic effects on triple-negative breast cancer. The inhibitor induces apoptosis in MDA-MB-231 cells by influencing metabolic pathways. Animal model experiments demonstrate significant therapeutic effects of the inhibitor.